Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange

被引:43
作者
Weinstein, R [1 ]
机构
[1] Tufts Univ, St Elizabeths Med Ctr Boston, Sch Med, Dept Med,Div Hematol Oncol & Transfus Med, Brighton, MA 02135 USA
关键词
ACD; citrate toxicity; ACE inhibitors; plasmapheresis;
D O I
10.1002/jca.10000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypocalcemic toxicity accounts for the most common adverse effects of therapeutic plasma exchange. The symptoms can be related to a fall in plasma ionized calcium. Citrate-based anticoagulants, notably sodium citrate and ACD formula A, have been indicated as the major cause of hypocalcemic toxicity, but colloid replacement fluids containing human serum albumin, are also at fault. Recognition of the signs and symptoms of hypocalcemic toxicity is important because several clinical measures are available to deal with them and to ensure patient comfort. A typical reactions, characterized by flushing and hypotension during plasma exchange, have been attributed to the effects of angiotensin converting enzyme inhibitors. Both exchange and adsorption apheresis procedures can result in atypical reactions in patients who have been taking this class of drugs within 48 to 72 hours of an apheresis procedure. These reactions are less common than hypocalcemic toxicity, but can be prevented by paying attention to detail. J. Clin. Apheresis 16:210-211, 2001. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:210 / 211
页数:2
相关论文
共 20 条
[1]   HYPOTENSION ASSOCIATED WITH PREKALLIKREIN ACTIVATOR (HAGEMAN-FACTOR FRAGMENTS) IN PLASMA-PROTEIN FRACTION [J].
ALVING, BM ;
HOJIMA, Y ;
PISANO, JJ ;
MASON, BL ;
BUCKINGHAM, RE ;
MOZEN, MM ;
FINLAYSON, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 299 (02) :66-70
[2]   APHERESIS AND ACE-INHIBITORS [J].
BRECHER, ME ;
OWEN, HG ;
COLLINS, ML .
TRANSFUSION, 1993, 33 (11) :963-964
[3]  
Chopek M, 1980, THERAPEUTIC HEMAPHER, P13
[4]   COMPLICATIONS OF THERAPEUTIC PLASMA-EXCHANGE - A RECENT ASSESSMENT [J].
COURIEL, D ;
WEINSTEIN, R .
JOURNAL OF CLINICAL APHERESIS, 1994, 9 (01) :1-5
[5]  
Goss GA, 1999, J CLIN APHERESIS, V14, P114, DOI 10.1002/(SICI)1098-1101(1999)14:3<114::AID-JCA2>3.0.CO
[6]  
2-8
[7]  
Hester J P, 1984, J Clin Apher, V2, P41, DOI 10.1002/jca.2920020109
[8]  
Hester J P, 1983, J Clin Apher, V1, P149, DOI 10.1002/jca.2920010306
[9]  
HUESTIS DW, 1989, ARCH PATHOL LAB MED, V113, P273
[10]  
*IMR CORP, 1993, SPEC PMA S